Patients with hepatocellular carcinoma (HCC) satisfying the Milan criteria are candidates for liver transplantation (LT), but locoregional therapies could be another options for them.
Introduction
A landmark study by Mazzaferro et al in 1996 [1] established deceased-donor liver transplantation (DDLT) as a valuable option for the treatment of hepatocellular carcinoma (HCC). [2] When liver transplantation (LT) is restricted to patients with early HCC, defined as a single lesion 5 cm, up to 3 separate lesions with none >3 cm, with no evidence of gross vascular invasion, and no regional nodal or distant metastases (known as the Milan criteria), a 4-year survival rate of 75% can be achieved. [1] These results have been validated, and with respect to any other available treatment for HCC, LT has the highest potential to cure, as it allows for removal at once of both the tumor and damaged hepatic tissue. [3] However, in most Asian countries, a serious shortage of deceased donors and a strong demand for LT has led to the development of living-donor LT (LDLT) as a practical alternative for DDLT. [4] LDLT is not limited by the restrictions imposed by the nationwide allocation system, and the decision for transplantation often depends on institutional or case-by-case considerations, balancing the will of the donor, the operative risk for both the donor and the recipient, and the overall survival benefit for the recipient. [5] In this respect, an important question arises as to whether there is a survival benefit of LT compared with locoregional therapies in early-stage HCC patients with preserved liver function. Hepatic resection can yield a comparable 5-year survival rate with minimal morbidity compared with LT in patients with early HCC who have adequate liver reserves. [6] Radiofrequency ablation (RFA) is another treatment option for early-stage tumors, [7, 8] and RFA for HCC conforming to the Milan criteria showed similar 5-year survival as did surgical resection. [9] Hence, it is still unclear which is better, LT or locoregional therapy in the treatment of HCC that was diagnosed within the Milan criteria, especially if a patient has preserved liver function or if a resection or RFA can be performed.
Therefore, this study was designed to see factors that determine survival of HCC patients diagnosed within the Milan criteria, stratified by those who received LT or who were managed with locoregional therapies. We compared survival rates between patients who received LT and those who did not with the aim of identifying factors that can be used to estimate survival of patients who were diagnosed within the Milan criteria, and did not undergo LT. These factors can help decide between LT versus locoregional therapy in cases diagnosed within the Milan criteria.
Methods

Study population
The HCC registry of Samsung Medical Center, Seoul, Korea, which enrolls treatment-naïve, newly diagnosed HCC patients who received care at Samsung Medical Center, Seoul, Korea, was used for this study. The registry began in January 2005. When patients are newly diagnosed with HCC, well-trained abstractors collect data, including age at diagnosis, sex, date of diagnosis, etiology, liver function (e.g., Child-Pugh [CP] class), tumor characteristics (e.g., number of tumors, maximal tumor size, the presence and extent of portal vein invasion, and type of extrahepatic spread), tumor stage, and initial treatment modality. HCC was diagnosed either histologically or clinically according to regional guidelines of HCC. [10, 11] Among a total of 3515 patients who were registered in the HCC registry between January 1, 2005 and December 31, 2009, we enrolled 1859 HCC patients fulfilling the Milan criteria at the time of HCC diagnosis. This study was reviewed and approved by the Institutional Review Board of Samsung Medical Center. Because the study is based on a retrospective analysis of existing administrative and clinical data, the requirement for obtaining informed patient consent was waived by the Institutional Review Board.
Variables, primary endpoint, and follow-up
Data on each patient included age, sex, etiology of liver disease, serum alphafetoprotein (AFP) levels, model for end-stage liver disease (MELD) score, Eastern Cooperative Oncology Group performance status (ECOG), CP class with score, tumor size, number, extent, and the presence of vessel invasion at the time of HCC diagnosis. Initial treatment modality for HCC was also recorded. The primary endpoint was overall survival, which was defined as the time from the primary diagnosis of HCC to death. All patients were followed up from baseline to June 2015. Patient survival data were collected from the National Statistics Service; therefore, all deaths at the time of survival assessment were certified. We also collected information regarding cause of death using the International Classification of Disease code that was recorded at death certificate of each patient. Liver-related death was defined when the cause of death was related to HCC or liver cirrhosis. For those who received curative treatment (LT, resection, or ablation), information on recurrence was collected.
Statistical analyses
Survival curves were estimated using the Kaplan-Meier method and compared using the log-rank test. Cox-regression analysis was conducted to compare overall survival between groups, adjusted for age. Age, sex, CP score, MELD score, aspartate to platelet ratio index, previous liver decompensation history, tumor number, tumor size, serum AFP levels, ECOG, and underlying liver disease were tested by random survival forest analysis. Decision tree analysis was conducted to detect survival nodes with similar survival risk using R 3.1.0 (Vienna, Austria).
Results
Baseline characteristics, treatment modalities, and survival
The baseline characteristics of the 1859 HCC patients fulfilling the Milan criteria are shown in Table 1 . The mean age of the patients was 57.3 years, and most were male (75.9%) with good performance (ECOG 0, 92.6%) and well-preserved liver function (CP score A, 85.1%). Median AFP level was 23.2 ng/mL. During follow-up, 130 patients received LT (7.0%); their characteristics are shown in Table 2 . LDLT was major form (106 patients, 81.5%) and median time from diagnosis to LT was 18.3 months. Thirty-four patients (26.2%) received LT without other therapy and 96 patients (73.8%) received one or more locoregional therapies before LT. At the time of LT, 113 patients (86.9%) were still within the Milan criteria (32 patients who received LT without other therapy and 81 patients who received LT following other therapies) and 17 patients (13.1%) had surpassed the Milan criteria (2 patients who received LT without other therapy and 15 patients who received LT following other therapies). Among 1729 patients who did not undergo LT, the major initial treatment modality was resection (n = 608, 35.2%) followed by RFA (n = 598, 34.5%) and transcatheter arterial chemoembolization (TACE) (n = 510, 29.5%). The median follow-up duration was 72.5 months (range: 0.4-122.9 months). The median survival had not been reached at the time of analysis, and the 5-year survival rate was 68.4%. Among 679 patients who died, 92.2% were liver-related mortality. HCC recurrence was observed in 10.8% (14/130), 43.1% (262/608), and 66.4% (397/598) of patients who underwent LT, resection, and RFA, respectively.
Survival nodes with similar survival in the non-LT group
By survival tree analysis, patients in the non-LT group were divided into 6 subgroups (nodes 1-6) with similar survival risks based on CP score, serum AFP level, tumor size, and age ( Fig. 1) . Node 1 was characterized by CP score 5 and serum AFP <5 ng/ mL. Node 2 was characterized by CP score 5, AFP ≥5 ng/mL, and tumor size <2.5 cm. Node 3 was characterized by CP score 5,
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Medicine AFP ≥5 ng/mL, and tumor size ≥2.5 cm. Node 4 was characterized by CP score 6 to 7 and age 65 years. Node 5 was characterized by CP score 6 to 7 and age >65 years. Node 6 was characterized by CP score ≥8. The 5-year survival rates of patients in nodes 1, 2, 3, 4, 5, and 6 were 87.3%, 77.5%, 65.8%, 64.7%, 44.0%, and 28.7%, respectively ( Fig. 2 ; Table 3 ). Liverrelated mortality was observed in 83.9%, 90.5%, 93.6%, 96.4%, 90.3%, and 97.3% of patients in nodes 1, 2, 3, 4, 5, and 6, respectively (P = 0.048). Initial treatment modality was also associated with survival. Overall, the 5-year survival rates were 82.6%, 70.9%, and 46.5% for patients who underwent resection, RFA, and TACE, respectively (P < 0.001). Among 1336 patients who received curative therapy (either LT, resection, or RFA), the recurrence rates were 10.8%, 37.8%, 57.4%, 52.5%, 65.4%, 65.0%, and 26.3% for LT, and nodes 1, 2, 3, 4, 5, and 6, respectively (P < 0.001). The overall-and recurrence-free survival rate differed according to the initial treatment modality in each survival node (Table 4) .
Overall survival according to LT
Among 130 patients with LT, 31 cases of mortality were observed. The liver-related mortality rate was 74.2% (23/31 patients). Among 8 patients with nonliver-related mortality, infectious complication was the most frequent cause of death Values are expressed as mean ± standard deviation, median (range) or number (percent), as appropriate. DDLT = deceased-donor liver transplantation, ECOG = Eastern Cooperative Oncology Group performance status, LDLT = living donor liver transplantation, LT = liver transplantation, MELD = model for end-stage liver disease, RFA = radiofrequency ablation, TACE = transarterial chemoembolization. Figure 1 . Survival tree analysis of hepatocellular carcinoma patients who did not undergo liver transplantation. Child-Pugh score, serum alphafetoprotein, tumor size, and age were factors that divide the survival tree.
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(4 cases). Liver-related mortality was less frequently observed in those who received LT than in those who received non-LT treatment (74.2% vs 93.1%, P < 0.001).
Overall survival was longer in patients who received LT (81.5% vs 67.4% at 5 years; 73.8% vs 61.1% at 10 years, P = 0.002). The unadjusted hazard ratio (HR) for overall survival (LT vs non-LT) was 0.58 (95% confidence interval [CI], 0.40-0.83) (P = 0.003). LT remained a significant factor for overall survival after adjustment for age, sex, CP class, tumor number, tumor size, serum AFP level, and ECOG status (HR = 0.46; 95% CI, 0.32-0.67, P < 0.001).
When patients who received LT were classified according to the same criteria used to categorize non-LT patients, there were no significant differences in survival by node; the 5-year survival rates were 83.3%, 78.6%, 84.6%, 81.1%, 75.0%, and 82.5% for nodes 1 (n = 6), 2 (n = 14), 3 (n = 13), 4 (n = 53), 5 (n = 4), and 6 (n = 40), respectively (P = 0.76). Therefore, when we compared survival according to LT in each node, the survival of all LT patients was used as a reference instead of that of LT patients in the corresponding node (Table 3) .
When stratified according to the purpose of LT (primary vs salvage) and tumor stage at the time of LT (within vs beyond the Milan criteria), the 5-year survival rate was 82.4% for patients who underwent primary LT (n = 34), 86.4% for patients who received locoregional therapies first and then salvage LT and who met the Milan criteria at the time of LT (n = 81), and 53.3% for patients who received locoregional therapies first and then salvage LT who had surpassed the Milan criteria (n = 15) (Fig. 3) . Two patients who received primary LT had stage migration at the time of LT. Baseline characteristics of patients who received LT within and beyond the Milan criteria were similar, except for tumor size (median: 1.8 vs 2.8 cm, P = 0.004). Overall survival and recurrence-free survival were better for those who received LT and met the Milan criteria compared with those who received LT who surpassed the Milan criteria at the time of LT (Table 4) .
Comparison of survival between LT versus each survival node (non-LT)
The overall survival rates of patients in nodes 1 and 2 in the non-LT group were similar to that in the LT group; however, the survival of patients in nodes 3, 4, 5, and 6 in the non-LT group were significantly worse (Fig. 2) . Unadjusted and age-adjusted HR for survival of each node (non-LT) vs LT was comparable in nodes 1 and 2, but significantly worse in nodes 3, 4, 5, and 6 (Table 3 ). For patients who received LT, tumor stage at the time of LT was associated with overall survival. For patients who received non-LT treatment, initial treatment modality was associated with patient survival. Thus, when each survival node was further stratified by initial treatment modality, resection produced even better survival than LT in node 1, similar survival in nodes 2, 3, 4, and 5, and worse survival in node 6 compared with patients who received LT within the Milan criteria (Table 4) . RFA showed similar survival to LT in nodes 1 and 2, and showed worse survival in nodes 3, 4, 5, and 6. TACE showed similar survival to LT only in node 1, and showed worse survival in the other survival nodes.
Discussion
In this study, the first factor that divided the survival probability of patients diagnosed within the Milan criteria who did not undergo LT was CP score. Those with CP score ≥8 (node 6) showed the worst 5-year survival rate (28.7%). Among patients with CP score 6 to 7, age was the next factor that classified patient survival risk (nodes 4 and 5). In patients with a CP score of 5, AFP and tumor size were the next factors that further classified patients (nodes 1, 2, and 3). This survival tree analysis clearly Figure 2 . Survival of patients. There were significant differences in overall survival rate by survival node and liver transplantation.
Table 3
Comparison of survival between each survival node and liver transplantation. demonstrated that for patients with decreased liver function, defined by CP score ≥6 (nodes 4, 5, and 6), the best treatment option is LT in terms of long-term survival. In case with preserved liver function (CP score 5), our data indicate that serum AFP and tumor size may help identify the subset of patients who might achieve survival benefit by LT. Node 1, which is characterized by preserved liver function (CP score 5) plus extremely low AFP levels (<5 ng/mL), and node 2, which is characterized by preserved liver function (CP score 5) plus small tumor (size <2.5 cm), showed similar survival to LT, whereas node 3, characterized by preserved liver function (CP score 5) but AFP ≥5 ng/mL and tumor size ≥2.5 cm), showed a lower survival rate than LT, indicating that LT is the best option for node 3, whereas locoregional therapies may be preferable in patients in nodes 1 and 2. The reason for the better survival following LT in patients with decreased liver function (nodes 4 to 6) can be explained because liver function is a well-known factor for patient survival in HCC, [12, 13] and LT can treat both the tumor and the damaged hepatic tissue. [3, 4] In patients with preserved liver function, LT provided a survival benefit compared with locoregional therapies in survival node 3, but not in nodes 1 and 2. AFP level is an important factor for prognosis in HCC. [14] [15] [16] Tumor size is also an important prognostic factor. [17, 18] Larger tumor size is an important risk factor for local tumor progression after RFA [7] ; it decreases the effect of locoregional treatment and increases the recurrence rate compared with smaller sized tumors. [19, 20] This data shows that similar long-term survival can be expected following non-LT treatment for patients with preserved liver function plus low AFP levels (node 1) or preserved liver function and small tumors (node 2).
For those who received LT, tumor stage at LT was associated with long-term outcome. Notably, only 34 patients underwent primary LT, with the remainder receiving one or more locoregional therapies to control HCC before LT (salvage LT). It is Table 4 Comparison of survival between treatment modality of each survival node and liver transplantation.
Patients group
No. of patients noteworthy that those who were still within the Milan criteria at the time of LT (86.4% at 5 years) displayed similar survival to those who underwent primary LT (82.4% at 5 years). Hence, as long as a patient stays within the Milan criteria, salvage LT, that is, liver resection (or other locoregional therapies) for HCC as a first-line treatment in transplantable patients followed by transplantation, is an attractive option. [21] Resection has been reported to be more cost-effective than LT for early HCC within the Milan criteria, [22] and performing LT too soon after diagnosis was suggested as a factor that adversely affect patient outcomes. [23] Similar outcomes after LT have also been reported between primary versus salvage LDLT. [24] In our series, 13.1% (17/130) of patients were transplanted after their tumor had progressed beyond the Milan criteria; those patients showed a significantly lower survival rate (53.3% at 5 years). Fuks et al also reported that 22% of transplantable patients became nontransplantable as the disease progressed beyond the Milan criteria when treated with logoregional therapies. [25] Microscopic vascular invasion, satellite nodules, and tumor size >3 cm poorly differentiated tumors, and liver cirrhosis are risk factors for the recurrence beyond Milan criteria. [25] In our analysis, large tumor size was associated with LT beyond the Milan criteria. When patients start therapy with non-LT treatment, there is a risk of stage migration (recurrence beyond the Milan criteria). Hence, while considering the salvage LDLT, one should be aware of the risk of stage migration following non-LT treatment, and the risk should be discussed carefully with the patient.
For those who did not receive LT, treatment modality was associated with long-term outcome. Resection showed better survival than RFA or TACE in each survival node. Thus, when compared with LT within the Milan criteria (Table 4) , resection showed even better survival than LT in node 1, similar survival in nodes 2, 3, 4, and 5, and worse survival in node 6. RFA showed similar survival to LT in nodes 1 and 2, and worse survival in nodes 3, 4, 5, and 6. TACE showed similar survival to LT only in node 1. Generally, patients who receive resection are carefully selected and have adequate liver functional reserves, [11] which explains why patients with resection showed better survival in each survival node. Yet, this finding illustrates that initial treatment modality can also affect long-term outcome. Hence, when estimating long-term outcome, one must consider the available treatment options for each patient. For example, similar long-term outcome to LT can be expected by resection or RFA for patients in node 2, but not with TACE. Likewise, similar longterm outcome to LT can be expected if resection can be done in survival node 3.
There are some limitations to this study. The retrospective design is an inherent limitation. Our survival tree analysis was based on baseline characteristics. However, several on-treatment factors can affect survival of HCC patients, such as treatment response, AFP levels after treatment, tumor recurrence, and subsequent treatment. [13] Likewise, recurrence of underlying disease (e.g., hepatitis C) and recurrence of tumor can affect long-term outcomes in patients who received LT. [26] HCC is notorious for its high recurrence rate, and treatment of recurrence affects long-term outcome, [27] yet this study analyzed the initial treatment only. More importantly, selection of the treatment modality was chosen by a respective physician. There is thus a selection bias regarding the choice of each treatment, and also there may be an unidentified or unrecorded bias. Tumor recurrence, cost, quality of life, and donor availability are other issues that need to be considered when selecting treatment modality. The study was conducted in a deceased donor resource-poor country, where LDLT is the major form of LT. The strength of this study is that it included a large number of HCC patients and that there was no follow-up loss in the survival statistics.
In summary, this study identified important determinants for survival that can be used to estimate survival of patients diagnosed within the Milan criteria, which can help doctors in choosing a first-line treatment option. Our data indicate that LT should be the first-line option for those with decreased liver function. For patients with preserved liver function, those with low serum AFP levels or small tumors showed comparable survival to LT, indicating that these 2 factors can be used to estimate survival of non-LT patients. For patients who received LT, baseline factors were not significantly linked to survival, yet tumor stage at the time of LT was associated with long-term outcome, indicating that when choosing locoregional therapy versus LT, one must consider the risk of tumor progression beyond the Milan criteria when managed with locoregional therapies. For patients receiving non-LT treatment, availability of a specific treatment modality (resection, RFA or TACE) also affected long-term outcome. In conclusion, CP score, serum AFP levels, tumor size, and age are baseline factors that can be used to estimate long-term outcomes in non-LT patients. Tumor progression beyond the Milan criteria and availability of specific treatment modalities also affected long-term outcomes. These factors may be used to estimate long-term outcomes of HCC patients diagnosed within the Milan criteria.
